Figure 1
Response rates to first-line docetaxel (D)–carboplatin (C) therapy in a dose-finding study of D 60–85 mg m−2 and C AUC 5–7 in women with ovarian cancer (73 evaluable for response) (Vasey et al, 2001).
Figure 1 | British Journal of Cancer
Response rates to first-line docetaxel (D)–carboplatin (C) therapy in a dose-finding study of D 60–85 mg m−2 and C AUC 5–7 in women with ovarian cancer (73 evaluable for response) (Vasey et al, 2001).
